ArticleHealth science reports2025
Gloves Standards and Occupational Exposure to Antineoplastic Drugs in the European Context.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Over 12 million healthcare professionals in Europe are exposed to hazardous medicinal products, including antineoplastic drugs. Dermal route is recognized as the primary route of exposure to antineoplastic drugs, emphasizing the critical importance of skin protection provided by gloves, which necessitates a careful and specific selection process. This study aims to compare the current European standard EN 16523-1:2015 + A1:2018 with the ASTM D6978-05(2023) standard used in the United States. Methods: Firstly, the three main performance parameters to consider when selecting gloves are described: standardized breakthrough time, standardized permeation rate, and cumulative permeation. Subsequently, the current European and American standards are compared based on the following criteria: part of the glove tested, substances tested, standardized permeation rate, test duration, test temperature, and the information provided on the glove packaging. Additionally, and with a focus on safety, clear examples of how to interpret graphical symbols and indications available on glove packaging are provided to enhance the transferability of the information contained in this study to healthcare settings. Results: There is a significant disparity between the requirements of the two standards. Indeed, the only European standard applicable in the context of glove permeation by antineoplastic drugs requires a standardized permeation rate 100 times less stringent than the American standard and does not include any hazardous drugs in its list of substances to be tested. By proposing a list of 24 antineoplastic drugs to be tested, a test temperature of 35 ± 2°C (compared with 23 ± 1°C in the European standard), and by specifically targeting the thinnest part of the glove, the American standard is closer to real-world conditions of use compared to its European counterpart. Conclusion: This study underscores the limitations of current European standard, advocating for regulatory updates to better protect healthcare professionals, while emphasizing the complexity of selecting appropriate gloves for antineoplastic and hazardous drug exposure. Clinical Trial Registration: Not concerned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.